It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. Humira heir Skyrizi has been slowly creeping up on ...
AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel ...
MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie has announced two positive updates for Canadians living with ulcerative colitis (UC). Canada’s Drug Agency (CDA-AMC) has recommended SKYRIZI ® ...
The company raised full year adjusted EPS guidance to between $11.88 and $12.08 and expects total net revenues of approximately $60.5 billion. Updated product assumptions include Skyrizi global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback